<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210702051760N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-29</date_registration>
      <primary_sponsor>The University of Lahore Teaching Hospital</primary_sponsor>
      <public_title>Effects of low-level laser therapy in addition to conventional physical therapy on pain and numbness</public_title>
      <acronym></acronym>
      <scientific_title>Effects of low-level laser therapy in addition to conventional physical therapy on pain and numbness of lower limb in patients with diabetic peripheral neuropathy: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>43</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57248</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Randomization description: Computer generated randomization assignments will be designed by an independent statistician and randomization will be done by one of the research team members who will not involve in patient recruitment or assessment or data analysis. The computer will randomly place the participants into control group and experimental group. The randomization assignments will be kept in opaque, sealed envelopes and unsealed by a researcher after baseline testing. Outcome assessors will be unaware of group assignment. The experiment will be started on the day after randomization, Blinding description: Only the participants will be blinded. As both groups will be treated in prone lying and both, the participant and the care provider, will be wearing laser protection goggles, the participants will not be able to identify whether the laser probe is emitting any rays or not.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Diabetic Peripheral Neuropathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In experimental group, patients will receive 20-25 minutes of therapy session including 5 minutes of LLLT on lumbosacral area and plantar surface of foot each, along with the conventional therapy, including TENS for 15 minutes on lumbosacral area and plantar surface of foot having rectangular wave, 100µs pulse width, 150Hz frequency and 20mA intensity. TENS will be used on both sites at the same time. The 19 diode cluster head of the Laser 755 model will be used which have a wavelength of 640 nm (visible) and 950 nm (infrared) and a power of 10 mW (visible) and 15 mW (infrared) respectively. The cluster head will have 9 visible laser diodes and 10 infrared diodes. This session will be given for 4 days a week, for 4 consecutive weeks. Intervention 2: Control group: The patients in this group will also receive the same treatment including TENS and LLLT but the laser unit will be switched off this time to get sham therapy. As the patient will be in prone lying with face turned downward and will be wearing protective goggles, so the participant will not be able to determine if the laser is turned off. 20-25 minutes of therapy session will be given in again in controlled group for 4 days a week, for 4 consecutive weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahzaib Anwer</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>4-B, Sadaat Street, Wahdat Colony,</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 42 35405234</telephone>
        <email>shahzaibanwer33@gmail.com</email>
        <affiliation>The University of Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahzaib Anwer</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>4-B, Sadaat street, Ghazali Park, Wahdat colony,</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 42 35405234</telephone>
        <email>shahzaibanwer33@gmail.com</email>
        <affiliation>The University of Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Both males and females
Age ranging from 45 to 70 years
Type II diabetes with clinical stage N2a of diabetic peripheral neuropathy
Peripheral neuropathic symptoms lasting for ≥ 6 months</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unstable glycemic index
Pregnancy
Some surgical cases such as knee replacement or any spinal surgery
Spinal stenosis, spinal compression or any other relative radiculopathy
Patients having malignancy and who have received radiotherapy treatment during last six months
Peripheral vascular disease or Claudication
Skin discoloration or skin ulcers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In experimental group, patients will receive 20-25 minutes of therapy session including 5 minutes of LLLT on lumbosacral area and plantar surface of foot each, along with the conventional therapy, including TENS for 15 minutes on lumbosacral area and plantar surface of foot having rectangular wave, 100µs pulse width, 150Hz frequency and 20mA intensity. TENS will be used on both sites at the same time. The 19 diode cluster head of the Laser 755 model will be used which have a wavelength of 640 nm (visible) and 950 nm (infrared) and a power of 10 mW (visible) and 15 mW (infrared) respectively. The cluster head will have 9 visible laser diodes and 10 infrared diodes. This session will be given for 4 days a week, for 4 consecutive weeks.</i_keyword>
      <i_keyword>Control group: The patients in this group will also receive the same treatment including TENS and LLLT but the laser unit will be switched off this time to get sham therapy. As the patient will be in prone lying with face turned downward and will be wearing protective goggles, so the participant will not be able to determine if the laser is turned off. 20-25 minutes of therapy session will be given in again in controlled group for 4 days a week, for 4 consecutive weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before intervention, after 2 weeks and after 4 weeks of intervention. Method of measurement: Visual Analogue Scale for Pain.</prim_outcome>
      <prim_outcome>Numbness. Timepoint: Before intervention, after 2 weeks and after 4 weeks of intervention. Method of measurement: Michigan Neuropathy Screening Instrument (MNSI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The University of Lahore Teaching Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-15</approval_date>
        <contact_name>Ethics committee of The University of Lahore</contact_name>
        <contact_address>1-Km Defence Road, near Bhuptian Chowk, Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
